Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07446322 · ClinicalTrials.gov registry record · Phase 2
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
A Phase 2 study, sponsored by Oncolytics Biotech.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07446322 is a Phase 2 study that is actively recruiting participants, run by Oncolytics Biotech. The registered enrollment target is 60 participants.
The verdict
NCT07446322, a Phase 2 study, is actively recruiting participants, sponsored by Oncolytics Biotech.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy.
Interventions
- DRUG Bevacizumab
- DRUG FOLFIRI
- DRUG Pelareorep
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-04-30 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07446322
The ClinicalTrials.gov registry entry for NCT07446322 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oncolytics Biotech, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT07446322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07446322 about?
NCT07446322 is a clinical study titled "FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer". This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy.
What is the current status of trial NCT07446322?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-04-30. Estimated completion is 2030-04-30.
What interventions are being tested in trial NCT07446322?
The interventions under investigation include: Bevacizumab (DRUG), FOLFIRI (DRUG), Pelareorep (DRUG).
Who is sponsoring clinical trial NCT07446322?
This trial is sponsored by Oncolytics Biotech, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.